Achievements and Bottlenecks of PEGylation in Nano-delivery Systems

被引：11

作者：

Shen, Ruoyu ^{[1
]}

Yuan, Hong ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China

来源：

CURRENT MEDICINAL CHEMISTRY | 2023年 / 30卷 / 12期

关键词：

PEGylation; drug delivery; bioconjugation; nanomedicine; anti-PEG antibody; PEG immunogenicity; ACCELERATED BLOOD CLEARANCE; ANTI-PEG ANTIBODIES; POLYETHYLENE-GLYCOL; POLY(ETHYLENE GLYCOL); PHOTOTHERMAL THERAPY; COVALENT ATTACHMENT; CIRCULATION TIME; MOLECULAR-WEIGHT; ABC PHENOMENON; LINKER LENGTH;

D O I：

10.2174/0929867329666220929152644

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Poly(ethylene glycol) (PEG) has been widely applied in the biomedical field as a gold standard. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles, also known as PEGylation, is a common method to improve the efficiency of drug delivery and pharmacokinetics in vivo. The effect of PEGylation on the in vivo fate of various formulations has been and continues to be extensively studied based on the successful PEGylation of proteins to improve in vivo circulation time and reduce immunogenicity. The PEG shell protects the particles from aggregation, immune recognition, and phagocytosis, thereby prolonging the in vivo circulation time. This article mainly describes the development background, advantages and applications of PEGylation in the field of drug delivery, its defects or development bottlenecks, and possible alternatives.

引用

页码：1386 / 1405

页数：20

共 153 条

[1] Ligand Density and Linker Length are Critical Factors for Multivalent Nanoparticle-Receptor Interactions [J].

Abstiens, Kathrin ;

Gregoritza, Manuel ;

Goepferich, Achim M. .

ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (01) :1311-1320

[2] The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage [J].

Abu Lila, Amr S. ;

Kiwada, Hiroshi ;

Ishida, Tatsuhiro .

JOURNAL OF CONTROLLED RELEASE, 2013, 172 (01) :38-47

[3]

ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582

[4]

ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578

[5] Forces between mica and end-grafted statistical copolymers of sulfobetaine and oligoethylene glycol in aqueous electrolyte solutions [J].

Ahmed, Syeda Tajin ;

Leckband, Deborah E. .

JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2022, 608 :1857-1867

[6] Perspectives, Tendencies, and Guidelines in Affinity-Based Strategies for the Recovery and Purification of PEGylated Proteins [J].

Alberto Mejia-Manzano, Luis ;

Vazquez-Villegas, Patricia ;

Gonzalez-Valdez, Jose .

ADVANCES IN POLYMER TECHNOLOGY, 2020, 2020

[7] FDA-approved poly(ethylene glycol)-protein conjugate drugs [J].

Alconcel, Steevens N. S. ;

Baas, Arnold S. ;

Maynard, Heather D. .

POLYMER CHEMISTRY, 2011, 2 (07) :1442-1448

[8] ADSORPTION OF CHAIN MOLECULES WITH A POLAR HEAD A-SCALING DESCRIPTION [J].

ALEXANDER, S .

JOURNAL DE PHYSIQUE, 1977, 38 (08) :983-987

[9] PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE [J].

ALLEN, TM ;

HANSEN, C .

BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) :133-141

[10] LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].

ALLEN, TM ;

HANSEN, C ;

MARTIN, F ;

REDEMANN, C ;

YAUYOUNG, A .

BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36

← 1 2 3 4 5 6 7 8 9 10 →